A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia (GESTA-SCORE)

October 30, 2026 updated by: Maria Goya, MD, PhD, Maternal-Infantil Vall d´Hebron Hospital

A Prospective Randomized Clinical Trial to Reduce Blood Pressure at One Year Postpartum in Women With Preeclampsia, With Non-randomized Comparison Cohorts of Women With Other Adverse Pregnancy Outcomes and Pregnancies Without Adverse Outcomes: GESTA-SCORE Trial

GESTA-SCORE is a prospective, randomized clinical trial designed to evaluate whether an early, personalized cardiovascular prevention strategy can achieve a clinically meaningful 6 mmHg reduction in systolic blood pressure at one year postpartum compared with guideline-based standard care in women with preeclampsia.

Women with preeclampsia will be randomly assigned in a 1:1 ratio to one of two groups. The Intervention group will receive a structured cardiovascular prevention program based on early identification of cardiovascular risk factors, personalized clinical assessment, digital health monitoring and targeted preventive interventions. The Standard care group will receive postpartum care, including blood pressure assessment, antihypertensive treatment when indicated, cardiovascular risk management and clinical follow-up, in accordance with current clinical practice guidelines. All participants will receive appropriate medical care, and no clinically indicated treatment will be withheld.

The study will also include two non-randomized observational comparison cohorts: women with other adverse pregnancy outcomes (APOs), such as gestational diabetes, preterm birth or fetal growth restriction, and women without APOs. These cohorts will help researchers understand differences in blood pressure evolution and cardiovascular recovery during the first year after childbirth.

Participants will undergo an initial cardiovascular assessment during the first six weeks postpartum, followed by scheduled assessments at 3, 6 and 12 months after delivery. Blood pressure will be measured at each assessment using a validated automated upper-arm device and a standardized protocol. After five minutes of seated rest, three consecutive measurements will be obtained, approximately one minute apart. The average of the second and third measurements will be used as the blood pressure value for each assessment.

The primary outcome will be mean systolic blood pressure at 12 months postpartum, comparing the Intervention and Standard care groups and adjusting for baseline systolic blood pressure measured during the first six weeks postpartum. The study is designed to detect a between-group difference of 6 mmHg.

Secondary objectives include evaluating hypertension, cardiometabolic and kidney health, lifestyle changes and differences in postpartum cardiovascular recovery between women with preeclampsia, other APOs and pregnancies without APOs.

GESTA-SCORE aims to establish whether early, personalized cardiovascular prevention can improve blood pressure control beyond current guideline-based care and contribute to more effective cardiovascular prevention after pregnancy.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

GESTA-SCORE investigates whether an early, structured cardiovascular prevention strategy improves postpartum blood pressure control beyond guideline-based standard care in women with preeclampsia. The rationale is that systematic identification of modifiable cardiovascular risk factors, combined with personalized management and digital health support, may improve the transition from pregnancy-related care to longer-term cardiovascular prevention.

The study combines a prospective, randomized, controlled trial in women with preeclampsia with two non-randomized observational comparison cohorts. Following a baseline cardiovascular assessment within six weeks after delivery, women with preeclampsia will be randomized in a 1:1 ratio to personalized cardiovascular prevention or guideline-based standard care. Follow-up assessments will take place at 3, 6 and 12 months postpartum.

The intervention integrates cardiovascular risk assessment with individualized preventive care. Clinical findings will guide blood pressure management, review and adjustment of antihypertensive treatment when indicated, cardiometabolic and kidney health assessment, and recommendations addressing modifiable lifestyle factors. Digital health monitoring will support participant engagement and clinical follow-up. Healthcare professionals will remain responsible for interpreting clinical information and making treatment decisions.

The standard care group will receive postpartum assessment and management according to applicable clinical practice guidelines, including antihypertensive treatment, cardiovascular risk management and referral when clinically indicated. The randomized comparison will assess the incremental benefit of the structured, personalized prevention pathway. All participants will receive clinically indicated care throughout the study.

The observational cohorts will include women with adverse pregnancy outcomes other than preeclampsia and women without adverse pregnancy outcomes. These participants will undergo cardiovascular assessments at the same scheduled postpartum time points while receiving appropriate usual care. Their inclusion will provide context for interpreting cardiovascular recovery after preeclampsia and allow assessment of differences in postpartum trajectories across pregnancy outcome groups. Comparisons involving these cohorts will be observational and will be interpreted separately from the randomized treatment comparison.

A standardized blood pressure measurement procedure will be applied across the randomized groups and observational cohorts to reduce measurement variability. Trained personnel will use validated automated upper-arm devices and appropriately sized cuffs after a seated rest period. Repeated readings will be obtained at each assessment using a consistent procedure. The timing of the baseline assessment relative to delivery will also be recorded.

The primary randomized comparison will account for baseline systolic blood pressure. Repeated follow-up assessments will characterize blood pressure evolution and cardiovascular recovery throughout the first postpartum year. Together, the randomized and observational components will evaluate the added value of structured prevention after preeclampsia and describe postpartum cardiovascular health across different pregnancy outcomes.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women aged 18 years or older.
  • Able to complete the baseline cardiovascular assessment within six weeks after delivery.
  • Belong to one of the following three mutually exclusive study cohorts:
  • Preeclampsia cohort: Women with preeclampsia during the index pregnancy who are eligible for randomization to the intervention or standard care group.
  • Other-APO cohort: Women whose index pregnancy was complicated by adverse pregnancy outcomes other than preeclampsia, including gestational diabetes, preterm birth before 37 weeks of gestation, or fetal growth restriction, defined as estimated fetal weight or birth weight below the 10th percentile according to the study protocol.
  • No-APO cohort: Women whose index pregnancy was not complicated by preeclampsia or any other adverse pregnancy outcome specified in the study protocol.
  • Able and willing to provide written informed consent and participate in scheduled follow-up assessments.

Exclusion Criteria:

  • History of major cardiovascular events or clinically significant cardiovascular disease, including myocardial infarction, angina, stroke, heart failure, resuscitated cardiac arrest, or atrial fibrillation.
  • Unable to provide informed consent.
  • Do not meet the eligibility criteria for any of the three predefined study cohorts.
  • Unable to complete the baseline cardiovascular assessment within six weeks after delivery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Stantard management

Women with preeclampsia randomized to receive standard postpartum clinical care according to current national and international clinical practice guidelines.

Experimental: Intervention group - images vision

Women with preeclampsia randomized to receive an early, structured, personalized cardiovascular prevention program in addition to guideline-based clinical care.

This is aimed at assessing whether such feedback can encourage the adoption of healthier lifestyles and enhance adherence to preventive treatments, thereby potentially reducing the incidence of postpartum hypertension and other cardiovascular diseases.

Components of the Intervention:

Vascular Imaging:

Women in the intervention group undergo advanced vascular imaging using ultrasound technology to detect the presence of arterial plaques vs. no information about vascular images in the standard manag group.

The images are analyzed to assess the extent of vascular health, focusing on areas typically affected by cardiovascular risks such as the carotid arteries.

Feedback Delivery:

Detailed results from the vascular imaging are provided to the participants in a comprehensible format by healthcare professionals specialized in cardiovascular health.

This feedback session includes a thorough explanation of the findings, highlighting areas of concern and potential risks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean systolic blood pressure at 12 months postpartum
Time Frame: From the delivery until 1 year after delivery

Mean systolic blood pressure measured using a validated automated upper-arm device after 5 minutes of seated rest. Three readings will be obtained approximately 1 minute apart; the average of the second and third will be used. Intervention and Standard care groups will be compared, adjusting for baseline systolic blood pressure.

From the delivery until 1 year after delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2027

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

January 20, 2025

First Submitted That Met QC Criteria

January 27, 2025

First Posted (Actual)

January 29, 2025

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 30, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Hospital Vall d'Hebron
  • GESTA-SCORE TRIAL (Other Identifier: Vall d'Hebron Hospital)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.